Interstitial pneumonia occurs in approximately 25% of patients with primary Sjögren's syndrome. Interstitial pneumonia combined with primary Sjögren's syndrome usually responds well to systemic steroids, and fatal cases are rare. Lymphocytic interstitial pneumonia shows diffuse infiltration of polyclonal B and T cells. Autologous stem cell transplantation is performed in cases of primary Sjögren's syndrome as an optional treatment when the condition responds poorly to conventional treatment. The hypothesis that primary Sjögren's syndrome improves after transplantation relies on the role of B-cell abnormalities in pathogenesis or the strong effects of immunosuppressive therapy. We experienced the case of a patient diagnosed with primary Sjögren's syndrome and lymphocytic interstitial pneumonia progression refractory to conventional treatment (steroid and immunosuppressive drugs) and cyclophosphamide pulse therapy. Our patient demonstrated improvement of lung manifestations and autoimmune disease activity after autologous stem cell transplantation.
Introduction
Primary Sjögren's syndrome (pSS) is a systemic inflammatory disease that involves the exocrine glands, including the salivary and lacrimal glands. Although the most important clinical symptom of this disease is dryness of the mouth, pSS can cause systemic extraglandular symptoms. Involvement of the lungs, although it is found in more than 50% of patients, is usually asymptomatic. However, lung involvement appears as the initial accompanying symptom in about 10% of patients (1) .
We performed autologous stem cell transplantation (SCT) in a pSS patient with lymphocyte interstitial pneumonia (LIP).
At the time of diagnosis, the patient's progressive inflammation was poorly controlled by steroid and immunosuppressive drug therapy. Improvements in both pSS and LIP were observed after autologous SCT. We describe this case and review the related literature in this paper.
Case Report
A 32-year-old man visited a local hospital due to fatigue, respiratory distress during exercise, dry eyes, and dry mouth. He was diagnosed with pSS in March 2007. LIP was suspected due to high-resolution computed tomography (HRCT) findings. The patient was treated with prednisolone, hydroxychloroquine, methotrexate, azathioprine, and pilocarpine, without improvement in his symptoms. He was then transferred to our hospital.
The patient was an office worker, and did not have a noteworthy medical or family history. He exhibited a chronically ill appearance. His heartbeat was regular, but his breath sounds revealed crackles in both lung fields. The patient had an oral ulcer. Abnormalities were not found in his abdomen or extremities upon physical examination.
The patient's blood pressure was 120/70 mmHg, his pulse was 78 beats/min, respirations were 20 breaths/min, and body temperature was 36.7 o C. In laboratory tests, his white blood positive with a speckled pattern, the anti-SSA antibody was positive, and the anti-SSB antibody was negative.
The arterial blood gas analysis revealed a pH of 7.469, a pO2 
Discussion
Extraglandular manifestations of pSS are present in 40% to 50% of patients, and result from the lymphocytic infiltration of epithelial tissues. The prevalence of pulmonary involve- We report a case of a patient with pSS and LIP who exhibited no improvement after previous conventional treatment for pneumonia, and in whom we performed autologous SCT.
The activity of the patient's pSS and LIP improved in terms of symptoms, inflammatory markers and HRCT findings.
Although autologous SCT is not considered as a first line treatment option in pSS, it could be considered for refractory extraglandular manifestations in pSS.
